Navigation Links
Early Registration Deadline on Monday for U.S. Conference on Rare Diseases and Orphan Products

Horsham, PA (PRWEB) September 13, 2013

The early registration deadline for the third annual U.S. Conference on Rare Diseases and Orphan Products is Monday, Sept. 16. Co-sponsored by the National Organization for Rare Disorders (NORD) and DIA in collaboration with the Food and Drug Administration (FDA) and EURORDIS (Rare Diseases Europe), the conference will take place from Oct. 7 to 9 at the Bethesda North Marriott Hotel & Conference Center in Bethesda, Md.

Key stakeholders in the rare disease community, including patient advocates, industry leaders, researchers, regulatory officials and investors, will benefit from interactive plenary and group sessions focusing on topics such as legislative updates, scientific advances and the investment outlook.

Panels and speakers will include:

  •     Keynote speaker Bill Corr, deputy secretary, U.S. Department of Health and Human Services
  •     The Affordable Care Act and the Rare Disease Community, Catherine Oakar, senior policy adviser, U.S. Department of Health and Human Services
  •     The Investment Environment for Orphan Drugs/Devices, David I. Scheer, president, Scheer & Company, Inc.
  •     The International Perspective on Orphan Drugs/Devices, Geoffrey McDonough, M.D., president and CEO, Swedish Orphan Biovitrum AB (Sobi)
  •     Patients and Industry: Partnership and Collaboration in Research Funding and FDA Review, Kari Luther Rosbeck, president and CEO, Tuberous Sclerosis Alliance
  •     How Payer Organizations Make Coverage Decisions for Orphan Drugs, J. Russell Teagarden, senior vice president of medical and scientific affairs, NORD
  •     The Health Care System of the Future, William Shrank, M.D., assistant clinical professor of medicine, Harvard Medical School, and associate physician of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital
  •     Managing Orphan Drug Recalls and Shortages, Pamela Williamson, senior vice president and global head of regulatory affairs and compliance, Genzyme, and Valerie Jensen, associate director of the Center for Drug Evaluation and Research, FDA
  •     Research Frontiers in Rare Diseases: The Next Opportunities, Anne Marie Finley, vice president of government relations and public policy, Celgene

Interact With Patient Advocates
Representatives of approximately 100 patient organizations will attend this year’s conference, providing opportunities for stakeholders to learn firsthand about patient needs and challenges and how to form partnerships to reach shared goals.

Register for the Conference Now
For more information or to register, visit the conference website. Early registration rates are available through Monday, Sept. 16. NORD and DIA have arranged for a discounted rate of $189 for a standard room at the Bethesda North Marriott Hotel & Conference Center. The rate is available until Sept. 23, or when the room block is filled. Follow instructions on the conference registration website for reserving a hotel room.

Attend the Pre-Conference FDA/EMA Orphan Product Designation and Grant Workshop

FDA and the European Medicines Agency (EMA) will co-host the FDA/EMA Orphan Product Designation and Grant Workshop on Oct. 4, at FDA’s White Oak Campus in Silver Spring, Md. The workshop will provide valuable information about the agencies’ orphan drug designation programs, the FDA Humanitarian Use Device designation program and the FDA Orphan Products Grants Program. There will be no registration fee for the workshop. For information and registration details, visit the FDA workshop website.


ABOUT NORD: NORD is a nonprofit organization established in 1983 by leaders of rare-disease patient organizations to represent all Americans affected by rare diseases. NORD provides programs of advocacy, education, research and patient/family services. We work closely with approximately 200 member organizations representing people with specific rare diseases. NORD has offices in Boston; Danbury, Conn.; and Washington, D.C. Learn more about NORD at

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. After Taking Diabetes Drug Actos for Nearly Seven Years, Florida Man Developed Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
2. Contract Research Organization WCCT Global Announces Acquisition of Early Phase Ophthalmology and Aesthetics Capabilities
3. Medicaid pays for nearly half of all births in the United States
4. JCI early table of contents for Sept. 9, 2013
5. KORT Physical Therapy and Healthcare Reform: Early Intervention Drives Costs Down for Patients, Insurance Companies
6. Covance and the Indiana CTSI to collaborate on early clinical research
7. New method for early detection of colon cancer
8. Diet Doc Medical Weight Loss Plans Now Helps Women Lose Weight Fast Before Early Pregnancy to Reduce Risks of Premature Death for their Children
9. Diet Doc Weight Loss Plans Reveals New Fat Loss Diet Pills to Eliminate Fat Before Early Pregnancy Weight Can Affect Future Offspring
10. Early Detection Services at Dedicated Breast Center
11. New screening strategy may catch ovarian cancer at early stages
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: ...
Breaking Medicine Technology: